JP2009173618A - Anti-inflammatory agent - Google Patents
Anti-inflammatory agent Download PDFInfo
- Publication number
- JP2009173618A JP2009173618A JP2008040652A JP2008040652A JP2009173618A JP 2009173618 A JP2009173618 A JP 2009173618A JP 2008040652 A JP2008040652 A JP 2008040652A JP 2008040652 A JP2008040652 A JP 2008040652A JP 2009173618 A JP2009173618 A JP 2009173618A
- Authority
- JP
- Japan
- Prior art keywords
- inflammatory
- food
- composition
- present
- ginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は抗炎症効果目的とした組成物、及び該組成物を含む飲食品又は医薬品に関する。 The present invention relates to a composition intended for an anti-inflammatory effect, and to a food or drink or a medicine containing the composition.
抗炎症作用を有する飲食品は、関節炎（関節リウマチ、変性性骨関節炎など）、腫脹、アレルギー性鼻炎、花粉症、皮膚などの炎症性疾患に対しての治療に有用である。抗炎症剤として医薬品ではステロイド性抗炎症薬（ベタメタゾン、デキサメタゾン、プレトニゾロン等）、非ステロイド性抗炎症薬（アセチルサリチル酸、ジクロフェナク、インドメタシン等）などが知られているが、いずれも副作用がある。食品ではグルコサミン、コンドロイチン、ＭＳＭ（メチルサルフォニルメタン）、アスタキサンチン、甜茶、デビルズクロー、カテキンなどが知られているが、より効果の高い新しい素材が求められている。 Foods and drinks having an anti-inflammatory action are useful for the treatment of inflammatory diseases such as arthritis (rheumatoid arthritis, degenerative osteoarthritis, etc.), swelling, allergic rhinitis, hay fever and skin. As anti-inflammatory agents, steroidal anti-inflammatory drugs (betamethasone, dexamethasone, pretonisolone, etc.) and nonsteroidal anti-inflammatory drugs (acetylsalicylic acid, diclofenac, indomethacin, etc.) are known as anti-inflammatory agents, but all have side effects. As foods, glucosamine, chondroitin, MSM (methylsulfonylmethane), astaxanthin, strawberry tea, devil's claw, catechin and the like are known, but new materials with higher effects are demanded.
チョウセンマキはイヌガヤ科イヌガヤ属の植物であり、日本産イヌガヤの変種である。外見も一般的なカヤとは異なり、濃緑色の細長く硬い葉が枝の周りに螺旋状に生えている。用途としては、主に観賞用として庭園などで栽培されたり生花に用いられたりしているが、成分の解析やそれの生理活性の有無などについてはほとんど研究されていない。従ってチョウセンマキに抗炎症作用があるという報告は全くない。 Datura is a plant belonging to the genus Inugaya, and is a variant of Inugaya from Japan. The appearance is different from general kaya, and dark green long and thin leaves grow spirally around the branches. As its use, it is cultivated mainly in ornamental gardens and used for fresh flowers, but little research has been done on the analysis of its components and the presence or absence of its physiological activity. Therefore, there is no report that Korean mushroom has an anti-inflammatory effect.
本発明は、抗炎症作用を有する組成物を提供し、ひいては該組成物を含有する飲食品又は医薬品を提供することにある。 An object of the present invention is to provide a composition having an anti-inflammatory action, and thus to provide a food or drink or a medicine containing the composition.
上記の課題を解決するために鋭意検討を重ねた結果、チョウセンマキに顕著な抗炎症作用があることを見出した。すなわち本発明は、以下の構成を有する。
（１）チョウセンマキの成分を含有することを特徴とする抗炎症組成物。
（２）上記（１）に記載の組成物を含有する飲食品又は医薬品。As a result of intensive studies in order to solve the above problems, it has been found that Kyakusenki has a remarkable anti-inflammatory effect. That is, the present invention has the following configuration.
(1) An anti-inflammatory composition characterized by containing a component of Korean mushroom.
(2) Food / beverage products or pharmaceuticals containing the composition as described in said (1).
本発明により、チョウセンマキの成分を含有することを特徴とする抗炎症組成物、及び該組成物を含有する飲食品又は医薬品を提供することができる。 ADVANTAGE OF THE INVENTION By this invention, the anti-inflammatory composition characterized by containing the component of a ginseng, and the food-drinks or pharmaceutical containing this composition can be provided.
本発明に関わるチョウセンマキは、植物全体（葉、枝）をそのままアルコールなどの有機溶媒で抽出した抽出物を用いることができる。 As the datura plant relating to the present invention, an extract obtained by directly extracting the whole plant (leaves, branches) with an organic solvent such as alcohol can be used.
本発明に関わる抗炎症剤を製造するには、上記の方法で製造したチョウセンマキの成分を用いることができ、常法に従って公知の医薬用無毒性担体と組み合わせて製剤化すればよい。本発明に関わる抗炎症剤は、種々の剤型での投与が可能であり、例えば、経口投与剤としては錠剤、顆粒剤、散剤、カプセル剤、ソフトカプセル剤などの固形剤、溶液剤、懸濁剤、乳化剤等の液剤、凍結乾燥剤等があげられ、これらの製剤は製剤上の常套手段により調製することができる。上記医薬用無毒性担体としては、例えば、グルコース、乳糖、ショ糖、でんぷん、マンニトール、デキストリン、脂肪酸グリセリド、ポリエチレングリコール、ヒドロキシエチルでんぷん、エチレングリコール、ポリオキシエチレンソルビタン脂肪酸エステル、アミノ酸、アルブミン、水、生理食塩水などが挙げられる。また、必要に応じて安定化剤、滑沢剤、湿潤剤、乳化剤、結合剤等の慣用の添加剤を適宜添加することができる。本発明に関わる抗炎症剤において、チョウセンマキ成分の投与量は、患者の年齢、体重、症状、疾患の程度、投与スケジュール、製剤形態等により、適宜選択、決定されるが、例えば、一日当たり生葉等価量として０．０１ｍｇ−１０ｇ／ｋｇ体重程度とされ、一日数回に分けて投与してもよい。 In order to produce the anti-inflammatory agent according to the present invention, the ginseng component produced by the above method can be used, and it may be formulated in combination with a known non-toxic pharmaceutical carrier according to a conventional method. The anti-inflammatory agent according to the present invention can be administered in various dosage forms. For example, as oral administration agents, solid agents such as tablets, granules, powders, capsules, soft capsules, solutions, suspensions And liquids such as emulsifiers and emulsifiers, freeze-dried agents and the like. These preparations can be prepared by conventional means in preparation. Examples of the non-toxic pharmaceutical carrier include glucose, lactose, sucrose, starch, mannitol, dextrin, fatty acid glyceride, polyethylene glycol, hydroxyethyl starch, ethylene glycol, polyoxyethylene sorbitan fatty acid ester, amino acid, albumin, water, Examples thereof include physiological saline. In addition, conventional additives such as stabilizers, lubricants, wetting agents, emulsifiers, binders and the like can be appropriately added as necessary. In the anti-inflammatory agent according to the present invention, the dose of the ginseng component is appropriately selected and determined according to the patient's age, weight, symptom, degree of disease, administration schedule, formulation form, etc. The equivalent amount is about 0.01 mg-10 g / kg body weight and may be administered in several divided doses a day.
また、本発明に関わるチョウセンマキは、毒性を有することは報告されていないことから、抗炎症作用を目的とした飲食品として摂取することもできる。本発明に関わるチョウセンマキの成分は、特定保健用食品、栄養機能食品、又は健康食品等として位置付けることができる。機能性食品としては、例えば、チョウセンマキの成分に適当な助剤を添加した後、慣用の手段を用いて、食用に適した状態、例えば、顆粒状、粒状、錠剤、カプセル剤、ソフトカプセル剤、ペースト状等に形成したものを用いることができる。この飲食品は、そのまま食用に供してもよく、また種々の食品（例えばハム、ソーセージ、かまぼこ、ちくわ、パン、バター、粉乳、菓子など）に添加して使用したり、水、酒類、果汁、牛乳、清涼飲料水等の飲物に添加して使用してもよい。かかる食品の形態における本発明のチョウセンマキの成分の摂取量は、年齢、体重、症状、疾患の程度、食品の形態等により適宜選択・決定されるが、例えば、一日当たり生葉等価量として０．０１ｍｇ−１０ｇ／ｋｇ体重程度とされ、一日数回に分けて投与してもよい。 In addition, the ginseng according to the present invention has not been reported to be toxic, so it can also be taken as a food or drink intended for anti-inflammatory action. The component of Korean ginger related to the present invention can be positioned as a food for specified health use, a nutritional functional food, a health food, or the like. As functional food, for example, after adding a suitable auxiliary agent to the component of Korean ginseng, using a conventional means, a state suitable for food, for example, granular, granular, tablet, capsule, soft capsule, What was formed in the paste form etc. can be used. This food and drink may be used for food as it is, and added to various foods (for example, ham, sausage, kamaboko, chikuwa, bread, butter, milk powder, confectionery, etc.), water, alcoholic beverages, fruit juice, You may add and use for drinks, such as milk and a soft drink. The intake amount of the component of the ginseng of the present invention in the form of the food is appropriately selected and determined depending on the age, weight, symptoms, degree of disease, form of the food, etc. The dosage may be about 01 mg-10 g / kg body weight, and may be administered in several divided doses per day.
以下に本発明をより詳細に説明するために実施例を挙げるが、本発明はこれらによって何ら限定されるものではない。 Examples are given below to describe the present invention in more detail, but the present invention is not limited by these.
実施例１ チョウセンマキ全草メタノール抽出物のカラゲニン誘発浮腫形成抑制作用
被験試料としてチョウセンマキ（Ｃｅｐｈａｌｏｔａｘｕｓ ｈａｒｒｉｎｇｔｏｎｉａ ｆ． ｆａｓｔｉｇｉａｔａ）のメタノール抽出物を用いた。チョウセンマキの葉・枝粗切物を（３６９ｇ）４倍量のメタノールに一日浸漬し、減圧乾固し、３２ｇの抽出物を得た。
６週齢の雄Ｓｔｄ：ｄｄＹマウスの両後ろ肢足蹠の容積と厚さを測定し（０時間の測定値）、蒸留水で懸濁したチョウセンマキメタノール抽出物（１０００ｍｇ／ｋｇ）を経口投与した。Ｃｏｎｔｒｏｌとして蒸留水のみを経口投与した。１時間後、右後ろ肢足蹠皮下へ生理食塩水で溶解した１％カラゲニンを５０μｌ、左後ろ肢足蹠皮下へ生理食塩水を５０μｌ注射投与した。注射の２時間後、４時間後に両後ろ肢の容積と厚さを測定した。それぞれの値は平均値±標準偏差を示す。有意差検定はＳｔｕｄｅｎｔのｔ−ｔｅｓｔによって行った。＊、＊＊、＊＊＊はそれぞれコントロールに対しｐ＜０．０５、ｐ＜０．０１、ｐ＜０．００５を示す。その結果を表１に示す。
The volume and thickness of both hind footpads of 6-week-old male Std: ddY mice were measured (measured values at 0 hour), and orally administered with Kyakushinki Methanol Extract (1000 mg / kg) suspended in distilled water. did. Only distilled water was orally administered as a control. One hour later, 50 μl of 1% carrageenan dissolved in physiological saline was subcutaneously injected into the right hind footpad, and 50 μl of physiological saline was injected subcutaneously into the left hind footpad. The volume and thickness of both hind limbs were measured 2 hours and 4 hours after injection. Each value represents an average value ± standard deviation. The significance test was performed by Student's t-test. *, **, and *** indicate p <0.05, p <0.01, and p <0.005, respectively, with respect to the control. The results are shown in Table 1.
これらのチョウセンマキ全草メタノール抽出物はマウスのカラゲニン誘発浮腫形成を有意に抑制することが明らかとなった。It was clarified that these mushroom whole plant methanol extracts significantly suppressed carrageenin-induced edema formation in mice.
実施例２ チョウセンマキ全草メタノール抽出物のＮＯ（一酸化窒素）産生抑制作用
実施例１で用いたチョウセンマキ全草メタノール抽出物抽出物を被験試料として用いた。
９６ｗｅｌｌ ｐｌａｔｅにＲＡＷ２６４．７細胞を２×１０５ｃｅｌｌ／ｗｅｌｌ（１００μｌ）とチョウセンマキ全草メタノール抽出物とＬＰＳ（１μｇ／ｍｌ）を含むメディウム（１００μｌ）を加えて１６〜２４時間培養した。培養後、測定用プレートに培養上澄（１００μｌ）を回収し、Ｇｒｉｅｓｓ試薬（１％Ｓｕｌｆａｎｉｌａｍｉｄｅ，０．１％Ｎ−ｎａｐｈｔｈｙｌｅｎｅｄｉａｍｉｎｅ・２ＨＣｌ ｉｎ ５％ Ｈ３ＰＯ４）を１００μｌ加え、１０分間程度放置後にプレートリーダーにてＯＤ５４０ｎｍを測定した。ＮａＮＯ２の標準液のＯＤを同時に測定し検量線を作成、メディウム中のＮＯ２を測定した。ＬＰＳのみを加えたＲＡＷ２６４．７細胞（Ｃｏｎｔｒｏｌ）のＮＯ産生量を１００％とした。それぞれの値は平均値±標準偏差を示す。＊、＊＊、＊＊＊はそれぞれコントロールに対しｐ＜０．０５、ｐ＜０．０１、ｐ＜０．００５を示す。結果を表２に示す。
RAW264.7 cells were added to a 96-well plate with 2 × 10 5 cells / well (100 μl), a medicinal mushroom whole plant methanol extract and medium (100 μl) containing LPS (1 μg / ml) and cultured for 16 to 24 hours. After culturing, the culture supernatant (100 μl) is collected on the measurement plate, and 100 μl of Griess reagent (1% Sulfurilamide, 0.1% N-naphthylenediamine · 2HCl in 5% H 3 PO 4 ) is added and left for about 10 minutes. OD540nm was measured with the plate reader. A calibration curve was prepared by simultaneously measuring the OD of the standard solution of NaNO 2 , and NO 2 in the medium was measured. The amount of NO produced by RAW264.7 cells (Control) to which only LPS was added was defined as 100%. Each value represents an average value ± standard deviation. *, **, and *** indicate p <0.05, p <0.01, and p <0.005, respectively, with respect to the control. The results are shown in Table 2.
この結果より、チョウセンマキ全草メタノール抽出物はＲＡＷ２６４．７（マウスマクロファージ様細）からのＮＯの産生を有意に胞抑制することが示された。From these results, it was shown that the total extract of Datura whole grass significantly suppresses the production of NO from RAW264.7 (mouse macrophage-like cells).
本発明により、チョウセンマキの成分を含有することを特徴とする抗炎症組成物及び該組成物を含有する飲食品又は医薬品提供することが可能となった。INDUSTRIAL APPLICABILITY According to the present invention, it is possible to provide an anti-inflammatory composition characterized by containing a component of Korean mushroom and a food or drink or a medicine containing the composition.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008040652A JP2009173618A (en) | 2008-01-25 | 2008-01-25 | Anti-inflammatory agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008040652A JP2009173618A (en) | 2008-01-25 | 2008-01-25 | Anti-inflammatory agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2009173618A true JP2009173618A (en) | 2009-08-06 |
Family
ID=41029115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008040652A Pending JP2009173618A (en) | 2008-01-25 | 2008-01-25 | Anti-inflammatory agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2009173618A (en) |
-
2008
- 2008-01-25 JP JP2008040652A patent/JP2009173618A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120225053A1 (en) | Compositions and methods for the prevention and treatment of conditions associated with inflamation | |
| KR101382400B1 (en) | Composition comprising Protaetia brevitarsis for preventing and treating Inflammatory Disorder | |
| TW201117821A (en) | Composition comprising curcuma longa extract together with curcuma zedoaria extract | |
| US20230082624A1 (en) | Composition, containing quisqualis indica extract, for preventing or treating prostatic hyperplasia | |
| Hwang et al. | The effect of polysaccharide extracted from the marine alga Capsosiphon fulvescens on ethanol administration | |
| JP3768795B2 (en) | Xanthine oxidase inhibitor | |
| WO2016159593A2 (en) | Pharmaceutical composition for preventing or treating inflammatory diseases, containing lactococcus chungangensis as active ingredient | |
| JP2008260695A (en) | Hepatopathy inhibitor | |
| KR101277266B1 (en) | A composition comprising of a sprout extract of Triticum aestivum for treating and preventing obesity disease | |
| KR101735061B1 (en) | Composition containing Artemisia annua extract, artemisinin or dihydroartemisinin for preventing or treating obesity | |
| JP4371431B2 (en) | Antiallergic composition | |
| KR101359728B1 (en) | Composition containing fraction of euphorbia humifusa willd or euphorbia supina rafin for treating or preventing inflammatory disease | |
| JP2009173618A (en) | Anti-inflammatory agent | |
| KR101620153B1 (en) | Composition for preventing or treating ostarthritis comprising Glehnia littoralis | |
| KR101332824B1 (en) | Pharmaceutical Compositions for Preventing or Treating Arthritis Comprising Euphorbia ebracteolata Extracts | |
| JP2006036787A (en) | Xanthine oxidase inhibitor | |
| JP6003018B2 (en) | Hepatoprotective agent, pharmaceutical composition, and composition for protecting cells, etc. | |
| JP2010100598A (en) | No (nitrogen monoxide) production inhibitor | |
| JP2007031302A (en) | Adiponectin production accelerator and metabolic syndrome preventive | |
| JP2010100599A (en) | Anti-inflammatory agent | |
| JP2010100600A (en) | Anti-inflammatory agent | |
| CN104997821A (en) | Use of Radix Peucedani extract in immune function improvement | |
| KR100771987B1 (en) | Composition containing Bokbunja extract with testosterone secretion enhancing effect as an active ingredient | |
| KR20160084990A (en) | A composition comprising a extract of Robinia pseudoacacia for prevention and treatment of Atherosclerosis, myocardial infarction, stroke, vascular dementia, liver disease, dyslipidemia or thrombosis | |
| JP2012131761A (en) | Anti-inflammatory agent |